AI Stock Memo: ABT - Abbott Laboratories - RankAlpha

ABT

Rating buyAI Memo

Abbott Laboratories

As of 2026-01-24/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-01-24 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

high

Horizon

—

Key catalyst

Regulatory / approval milestones (window) • 2026-04-24

Expected move: +65%

Biggest risk

Prolonged diagnostics weakness, reimbursement pressure, or regulatory setbacks keep multiples near the analyst low.

Invalidation

Break below $108 or thesis failure.

What would change my mind?

Execution on device launches, margin recovery, and stronger diagnostics demand drive re-rating toward peer multiples and the bull target.

Research note

Recommendation

buy

Confidence

high

As of

2026-01-24

Base target

$141

p=60%

Bull target

$170

p=20%

Bear target

$108

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Next quarterly results (estimated)
Diagnostics and devices recovery
Execution on device launches, margin recovery, and stronger diagnostics demand drive re-rating toward peer multiples and the bull target.

BearKey bullets

Regulatory approval delays or adverse outcomes
Reimbursement pressure or prolonged margin compression
Sustained weakness in diagnostics volumes

WatchKey bullets

Regulatory / approval milestones (window)

Summary

High-level snapshot

Recommendation

buy

Model confidence

high

Timeframe

Asset

Equity

Trigger

Base case: $141 (p=60%)

Bull/Bear spread: +99% / +26%

Vs latest close: Bull +99% · Base +65% · Bear +26%

Scenario probabilities

Bull Target: $170 (p=20%)Base Target: $141 (p=60%)Bear Target: $108 (p=20%)

Commentary

Near-term tone turned negative after Jan 22 results due to a revenue miss and softer 2026 guidance, but analyst targets and dividend yield arguments keep longer-term sentiment constructive; filings show active insider/institutional moves that have increased debate and volatility.

As of 2026-01-24 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Execution on device launches, margin recovery, and stronger diagnostics demand drive re-rating toward peer multiples and the bull target.

Bear Case

Prolonged diagnostics weakness, reimbursement pressure, or regulatory setbacks keep multiples near the analyst low.

Drivers

Scannable catalysts and supporting factors

Next quarterly results (estimated)
Diagnostics and devices recovery

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-01-24Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$141.25

Range (USD)

$108.00 - $170.10

Count

Query: Abbott Laboratories Common (ABT) analyst consensus price target high low average

Abbott Laboratories (ABT) Stock Forecast, Price Targets ... - TipRanks
Search result #1
The average price target is $150.07 with a high forecast of $169.00 and a low forecast of $144.00. The average price target represents a 24.30% change from the ...
Extracted: $150.07, $169.00, $144.00Open source
Abbott (ABT) Stock Forecast & Price Target
Search result #2
According to projections from 25 analysts, the average 12-month price target for Abbott Labs is 140.95, with a high estimate of 169 and a low estimate of ...
Open source
Abbott (ABT) Price Targets - Zacks Investment Research
Search result #3
The forecasts range from a low of $130.00 to a high of $169.00. The average price target represents an increase of 34.73% from the last closing price of $108. ...
Extracted: $130.00, $169.00, $108.00Open source
Abbott Laboratories (ABT) Analyst Ratings, Estimates & ...
Search result #4
See Abbott Laboratories (ABT) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.
Open source
Abbott Laboratories Stock Forecast | ABT Price Target & Analyst ...
Search result #5
Highest Price Target. $169.00 (39.6%) ; Average Price Target. $151.50 (25.2%) ; Lowest Price Target. $140.00 (15.7%).
Extracted: $169.00, $151.50, $140.00Open source
Abbott Laboratories Analyst Estimates - ABT
Search result #6
Stock Price Targets. High, $169.00. Median, $137.00. Low, $123.00. Average, $139.09. Current Price, $108.61. Yearly Numbers. Estimates. ABT will report 2026 ...
Extracted: $169.00, $137.00, $123.00, $139.09, $108.61Open source

Scenarios

Bull Target (Scenario probability)

$170 / p=20% prob

Base Target (Scenario probability)

$141 / p=60% prob

Bear Target (Scenario probability)

$108 / p=20% prob

Price $86 as of 2026-05-29

Nearest Scenario: Bear (∆ 26%)

Targets vs latest close: Bull +99% · Base +65% · Bear +26%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-04-24
Regulatory / approval milestones (window)
Discrete regulatory or labeling decisions for devices remain material event risks/rewards; no single public date found, so date set to conservative near-term window end.
Prob 30.00% • Move 15.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

Next quarterly results (estimated)
2026-04-24
Next quarterly report is the nearest price catalyst; date conservatively estimated as an upcoming earnings window and likely to move shares on beats/misses.
Prob 70% • Move 8% • Priced-in 50%

Long-term Catalysts

Months to a year

Diagnostics and devices recovery
2027-01-24
Sustained recovery in diagnostics demand and device sales could drive multi-quarter upside, consistent with analyst upside scenarios.
Prob 60% • Move 25% • Priced-in 40%

Risks

Regulatory approval delays or adverse outcomes
Reimbursement pressure or prolonged margin compression
Sustained weakness in diagnostics volumes

Peers

Symbol	Summary
JNJ	Diversified healthcare conglomerate; useful benchmark for device/diagnostics mix and valuation.
MDT	Pure-play devices peer with comparable regulatory exposure and procedure-volume sensitivity.
BDX	Diagnostics/medtech peer; reference for diagnostics demand cycles and OEM channel dynamics.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Abbott Laboratories Common (ABT) analyst consensus price target high low average
Analysis date: 2026-01-24